- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02046408
Computer-Facilitated 5A's for Smoking Cessation in Primary Care
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This project develops and tests a computer-facilitated 5A's (CF-5A's) model that administers the 5A's intervention to patients then prompts providers for reinforcing next steps. CF-5A's could efficiently and effectively promote smoking cessation while educating providers about cessation resources and appropriate follow-up. Based on the Technology Acceptance Model, clinically tailored strategies to promote CF-5A's implementation will be developed and tested to ensure the appropriate use and uptake of this new service delivery model. Development of the model, materials, and strategies will occur in years 1 and 2.
Baseline data collection occurs in year 2, followed by a randomized trial of CF- 5A's where the provider is the unit of randomization. Provider use of the 5A's will primarily be assessed with a brief phone call to the patient after the primary care visit has occurred.
Although focused on 5A's for smoking cessation, this study examines the underlying implementation science of computer-aided service delivery models with important implications for the integration of other substance use or behavioral health interventions in primary care. Implementation factors will be assessed using qualitative interviews and brief pre-post surveys.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
California
-
San Francisco, California, Förenta staterna, 94110
- San Francisco General Hospital
-
San Francisco, California, Förenta staterna, 94115
- UCSF Adult Primary Care Mt. Zion Clinic
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria: All primary care providers and clinic staff are eligible to participate. Patients must have
- a primary care appointment
- smoked a cigarette in past 7 days
- smoked at least 100 cigarettes in lifetime
- speak English or Spanish
- be cognitively able to use computer tablet
Exclusion Criteria:
- Moderate to severe cognitive impairment
- Does not speak English or Spanish
- acute intoxication on alcohol or illicit drugs
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: Randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Tablet Intervention
Primary care providers will be randomized into intervention or control conditions.
The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling.
Patients of control providers will not receive a tablet intervention.
|
|
Inget ingripande: Control
Primary care providers will be randomized into intervention or control conditions.
The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling.
Patients of control providers will not receive a tablet intervention.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
5A's Fidelity
Tidsram: Baseline assessment 2013-14; Intervention 2014-2015
|
Baseline and post-tablet intervention assessments of primary care provider adherence to 5A's protocol for smoking cessation.
Patients are called after their primary care appointment and asked a series of questions to determine if (and which of) the 5A's were used during that visit.
|
Baseline assessment 2013-14; Intervention 2014-2015
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Tablet Usage
Tidsram: 7/2014-7/2015
|
Intervention includes system strategies to improve usage of computer tablets in primary care waiting rooms.
Outcome = tablet saturation or proportion of patients given a tablet.
|
7/2014-7/2015
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Implementation Factors
Tidsram: July 2013-2015
|
Qualitative interview data to assess the utility of the "Technology Acceptance Model" in explaining tablet and 5A's usage.
Variables assessed include perceived usefulness, social norms and influence, and facilitating conditions.
|
July 2013-2015
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Jason M Satterfield, PhD, University of California
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 1R01DA034253-01 (U.S.S. NIH-anslag/kontrakt)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Computer Tablet
-
Kowa Research Institute, Inc.Avslutad
-
HeNan Sincere Biotech Co., LtdOkänd
-
Shinshu UniversityRekrytering
-
GlaxoSmithKlineAvslutadHjärtsvikt, kongestivFörenta staterna
-
Daewoong Pharmaceutical Co. LTD.RekryteringDiabetes mellitus, typ 2Korea, Republiken av
-
Assuta Hospital SystemsAvslutad
-
Xuanzhu Biopharmaceutical Co., Ltd.RekryteringNonalkoholisk Steatohepatit (NASH)Kina
-
Giovanni CioniAzienda USL Toscana Nord Ovest; Scuola Superiore Sant'Anna di PisaRekryteringMedfödda och förvärvade utvecklingsstörningarItalien
-
IRCCS San Raffaele RomaRekrytering
-
University Hospital, Clermont-FerrandDr Gisèle PICKERING (MCU-PH)(Clinical Pharmacology center, Inserm 501); Dr Gilles DUCHEIX (Attaché)(Clinical Pharmacology center, Inserm 501)Avslutad